Trial intelligence / Profile preview

Phase 2a open-label study of AL-335 + odalasvir + simeprevir in Japanese subjects with chronic hepatitis C genotype 1 or 2

jRCT2080223413Phase 2

Sponsor

Janssen Pharmaceutical

Start

Dec 2016

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1